Clinical outcomes in adult patients with plaque psoriasis tr
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
In order to determine drug safety and efficacy in real-world practise, postmarketing surveillance is performed. The objective of the researchers was to verify the efficacy and protection of ustekinumab in the treatment of plaque psoriasis in adult Korean patients.

In a prospective, observational, and multi-center study, 977 subjects aged 18 years or older who were treated with ustekinumab for plaque psoriasis were enrolled. 654 (66.9%) were men, with mean body surface area (BSA, ± standard deviation) of 27.0 ± 18.3% and mean psoriasis area severity index (PASI) score of 18.1 ± 9.7.

The effectiveness analysis was performed in 581 patients who had at least one follow-up assessment and met treatment criteria per local label and reimbursement guidelines.

Results:
--Of these patients, 287 had effectiveness data for visit 6 at 53.7 ± 2.1 weeks. At visit 6, 91.6% (263/287), 51.2% (147/287), and 9.4% (27/287) patients achieved PASI 75, 90, and 100 responses, respectively.

--Adverse events (AEs) occurred in 112 of the 977 (11.5%) patients with an incidence rate of 21.5 per 100 patient years (PYs).

--Serious AEs occurred in eight (0.8%) patients with an incidence rate of 1.2 per 100 PYs. The estimated 1 year drug survival rate was 87.7%.

--The multiple logistic regression analysis showed that higher baseline PASI score and no prior biologic exposure were significant predictors for PASI 90 response at visit 6.

In conclusion, Ustekinumab was successful and healthy and demonstrated a high survival rate in real-world practise in the care of adult Korean patients with plaque psoriasis.

Source: https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.15670
Like
Comment
Share